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AbstrACt
Objective To investigate the efficacy of a standardised 
brief acupuncture approach for women with moderate-to-
severe menopausal symptoms.
Design Randomised and controlled, with 1:1 allocation to 
the intervention group or the control group. The assessor 
and the statistician were blinded.
setting Nine Danish primary care practices.
Participants 70 women with moderate-to-severe 
menopausal symptoms and nine general practitioners with 
accredited education in acupuncture.
Intervention The acupuncture style was western 
medical with a standardised approach in the predefined 
acupuncture points CV-3, CV-4, LR-8, SP-6 and SP-9. 
The intervention group received one treatment for five 
consecutive weeks. The control group was offered 
treatment after 6 weeks.
Main outcome measures Outcomes were the differences 
between the randomisation groups in changes to mean 
scores using the scales in the MenoScores Questionnaire, 
measured from baseline to week 6. The primary outcome 
was the hot flushes scale; the secondary outcomes were 
the other scales in the questionnaire. All analyses were 
based on intention-to-treat analysis.
results 36 participants received the intervention, and 34 
participants were in the control group. Four participants 
dropped out before week 6. The acupuncture intervention 
significantly decreased hot flushes: Δ −1.6 (95% CI [−2.3 
to −0.8]; p<0.0001), day-and-night sweats: Δ −1.2 
(95% CI [−2.0 to −0.4]; p=0.0056), general sweating: Δ 
−0.9(95% CI [−1.6 to −0.2]; p=0.0086), menopausal-
specific sleeping problems: Δ −1.8 (95% CI [−2.7 to 
−1.0]; p<0.0001), emotional symptoms: Δ −3.4 (95% 
CI [−5.3 to −1.4]; p=0.0008), physical symptoms: Δ 
−1.7 (95% CI [−3 to −0.4]; p=0.010) and skin and hair 
symptoms: Δ −1.5 (95% CI [−2.5 to −0.6]; p=0.0021) 
compared with the control group at the 6-week follow-
up. The pattern of decrease in hot flushes, emotional 
symptoms, skin and hair symptoms was already apparent 
3 weeks into the study. Mild potential adverse effects were 
reported by four participants, but no severe adverse effects 
were reported.
Conclusions The standardised and brief acupuncture 
treatment produced a fast and clinically relevant reduction 
in moderate-to-severe menopausal symptoms during the 
six-week intervention. No severe adverse effects were 
reported.
trial registration number NCT02746497; Results.
IntrODuCtIOn 
Experience of menopausal symptoms is 
very common and has been shown to affect 
quality of life, health status, work productivity 
and use of health services.1–3 The majority 
of women experience menopause in their 
early 50s4 and have menopausal symptoms 
for 4–5 years on average.4–7 The most prom-
inent symptom of menopause is hot flushes, 
which affect around 75% of menopausal 
women5 6 8 and is reported as very distressing 
by 10%–20%.5 Other reported menopausal 
symptoms are night sweats, emotional vulner-
ability, sleep disturbances, fatigue, cognitive 
changes, joint pain, vaginal dryness and loss 
of sexual desire.4 5 9 
strengths and limitations of this study
 ► This study has high methodological quality, alloca-
tion concealment, adequate power, a validated out-
come measure, sufficient and transparent reporting 
leading to high external validity.
 ► The study had high participants adherence support-
ing that the intervention was manageable and well 
tolerated.
 ► Since the intervention was pragmatic, standardised 
and brief, the applicability of the findings is high 
and might have a good chance of being implement-
ed, which could lead to new treatment options for 
menopausal women.
 ► At present, no sufficient acupuncture placebo com-
parator exists, which is a major limitation in acu-
puncture studies, this study included.
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Hormone therapy (HT) relieves menopausal symp-
toms,10 11 but long-term HT is associated with an increased 
risk of breast cancer and thromboembolic disorders.11–14 
Hence, many menopausal women avoid HT. Non-hor-
monal-based treatments such as clonidine, gabapentin 
and antidepressants may also reduce menopausal symp-
toms. However, these drugs have frequent adverse effects 
such as sleep disturbance, dizziness, nausea, fatigue, dry 
mouth and constipation.4 5 8 15 16 Non-pharmaceutical 
treatments, for example, relaxation, exercise, herbal 
remedies and diets containing phytoestrogens have been 
suggested, although there is a lack of knowledge about 
dose, duration and for herbal remedies and phytoestro-
gens, drug interactions and adverse effects. There is 
currently no convincing evidence of any beneficial effect 
from these treatments.4 8 15–17
Several studies have demonstrated the effects of 
acupuncture on menopausal symptoms,15 18–20 but they 
have been criticised for methodological limitations, 
for example, poor design, inadequate sample size, inade-
quate control or placebo groups, absence of standardised 
protocols and a lack of data on adverse effects.18 19 Further-
more, due to different methods and a lack of validation 
of some outcome measures, comparison of results is 
difficult.18 19 Therefore, further high-quality randomised 
acupuncture trials are needed.18 19 Although the use of 
acupuncture differs between countries, it is sought by 
many patients21–24 and practised by a substantial number 
of physicians, especially general practitioners (GPs).22 25–27 
If a clinically relevant effect on menopausal symptoms 
from acupuncture is demonstrated, this treatment may 
be considered for implementation in primary health-
care, leading to new options for menopausal women who 
cannot or do not wish to use HT.
We hypothesised that a brief and standardised acupunc-
ture treatment could reduce moderate-to-severe meno-
pausal symptoms, and in particular, it could have a 
clinically relevant effect in the reduction of hot flushes. 
Therefore, the objective of this study was to investigate 
the efficacy of a standardised brief acupuncture approach 
for women with moderate-to-severe menopausal symp-
toms, primarily the efficacy on hot flushes measured as 
change from baseline to week 6.
MethOD
trial design
The study was a randomised controlled trial (RCT) with 
a 1:1 allocation to the intervention or the control group. 
A detailed description of the methods used in the present 
study are found in the published protocol.28
settings and acupuncturists
The study took place in nine primary care practices in 
both urban and rural settings. The acupuncturists were 
nine GPs, and all but one were educated in acupuncture 
by the Danish Society for Evidence-based Acupuncture 
(DSEA) or the Danish Medical Acupuncture Society 
(DMAS). One GP had acupuncture training in Sri Lanka 
before DSEA and DMAS were formed. Participating GPs 
had, on average, 153 hours of acupuncture education 
(range 80–300) and had practised acupuncture for 14 
years (range 4–38 years).
The first author (KSL) held an individual meeting 
with each of the GP acupuncturists and provided them 
with the study protocol, an overview of the predefined 
acupuncture points and a written manual with precise 
instructions for treatment. KSL asked the GP acupunctur-
ists to behave neutrally and to provide only the specified 
acupuncture treatment and no other treatment or coun-
selling. A 2.5-hour refresher course on the predefined 
acupuncture points and techniques was offered, and four 
GPs attended this course.
Participants
Women were recruited through local newspapers, general 
practices close to the participating GP acupuncturist, the 
DSEA and the DMAS. Recruitment took place between 
late September 2016 and mid-December 2016.
Inclusion criteria: women aged 40–65 years with 
moderate-to-severe hot flushes (score ≥4 on a validated 
scale measuring hot flushes (MenoScores Question-
naire [MSQ]29 and online supplementary appendix 1), 
intact cognitive function and a valid email address. Before 
enrolment, participants gave written informed consent. 
Exclusion criteria: women who had had a hysterectomy 
and/or bilateral oophorectomy; women whose alcohol 
consumption exceeded 21 drinks per week; who used 
prescribed sleeping pills and/or prescribed sedatives; 
who had previously been diagnosed with breast, endome-
trial, cervical or ovarian cancer; who had been diagnosed 
with other severe cancer disease within the past 5 years; 
who had heart valve disease; who were insulin dependent 
and/or had poorly controlled diabetes mellitus; who were 
diagnosed with thyroid disease; who were under investi-
gation for serious disease, for example, cancer; who had 
received acupuncture treatment within the past 6 months; 
who had been pregnant or had been breast feeding within 
the past 2 years; who were participating in another trial 
or had participated in another trial in the 2 weeks before 
screening for eligibility; who, within the past 4 weeks, had 
used one or more of the following treatments: systemic 
HT, hormonal intrauterine device, antidepressants and/
or antiepileptics; and who had received other medical 
treatment for hot flushes (eg, clonidine), herbal reme-
dies/alternative treatments for menopausal symptom or 
corticosteroids (the use of inhaled steroids was not an 
exclusion criterion).
Enrolled participants were provided with oral and 
written information about the study.30 Participation was 
voluntary, and there was no payment for taking part. 
Participants could withdraw their consent at any time. 
The first author carried out assessment of eligibility, 
obtained informed consent and collected baseline char-
acteristic data.
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Intervention
All participants were offered one treatment per week for 
5 weeks by a GP acupuncturist in their local area. The 
intervention group received their treatment in the first 
5 weeks after enrolment in the study. At present, no vali-
dated acupuncture placebo comparator exists,31 32 and 
we decided to use a control group instead. The control 
group received their treatment after 6 weeks. Hence, 
this RCT is evaluated over a 6-week study period (online 
supplementary appendix 2; time schedule). No other 
treatment (medicine or alternative remedies) for meno-
pausal symptoms was allowed in any of the groups 
beginning 4 weeks prior to enrolment until study week 
11. The acupuncture style we used was western medical 
acupuncture (WMA),32 33 with a standardised approach 
and predefined acupuncture points (table 1 and online 
supplementary appendix 3), based on reports from expe-
rienced western medical acupuncturists.34
A complete acupuncture session should not last more 
than 15 min, including insertion of needles, retention 
time, removal of needles and documentation. Disposable 
sterile (Plandent) needles, size 0.30×30 mm, were inserted 
perpendicularly and rotated manually for a few seconds 
to elicit ‘de-qi’ (needle sensation, a feeling of heaviness 
around the acupuncture point).33 The predefined points 
were CV-3, CV-4, LR-8, SP-6 and SP-9 (table 1). A total of 
eight points was used, as LR-8, SP-6 and SP-9 were given 
bilaterally. Needle retention time was 10 min.
After each treatment, the GP acupuncturist completed 
a documentation scheme with the date, documentation 
for insertion of each of the needles and whether ‘de-qi’ 
was obtained. After the final treatment, the completed 
documentation was sent to the first author.
Outcome
The study’s outcomes were the differences between 
the randomisation groups in the mean change over 
the 6-week study period measured in the scales of the 
MSQ.29 The MSQ is a content-specific patient-reported 
outcome measure (PROM) with high-content validity 
and adequate psychometric properties measuring bother-
some menopausal symptoms. The MSQ encompasses 11 
scales and one single item (51 items in total), measuring 
different menopausal domains of bothersome symptoms 
(online supplementary appendix 1). The MSQ scales are 
constructed such that higher scores denote more bother-
some symptoms.
The primary outcome was the hot flushes (HF) 
scale, secondary outcomes were the remaining MSQ 
scales: day-and-night sweats (DNS), general sweating 
(GS), menopausal-specific sleeping problems (MSSP), 
emotional symptoms (EM), memory changes (MEM), 
skin and hair symptoms (SH), physical symptoms (PHY), 
abdominal symptoms (ABD), urinary and vaginal symp-
toms (URIN), sexual symptoms (SEX) and the single-
item tiredness (TR).
Of these MSQ scales, the HF, DNS, GS and MSSP scales 
are most related to menopause, while the other MSQ 
scales are more related to general ageing or other life 
events.29
Assessments and follow-up
All participants received the MSQ by email in study weeks 
0, 3, 6, 8, 11 and 26 (online supplementary appendix 2). 
Week 0 (before randomisation), week 3 (intermediate 
assessment) and week 6 (final assessment) are reported in 
the present manuscript. In the period when participants 
were receiving acupuncture treatment, we asked them to 
complete the MSQ 1–2 days before the third treatment 
and 1 week after the fifth and last treatment (online 
supplementary appendix 2). Participants completed 
and returned the MSQ electronically. Reminders were 
sent within 1–2 days, if the participant did not return a 
completed MSQ within the scheduled time. Additionally, 
participants in the intervention group were asked about 
adverse effects at the 3-week and 6-week follow-up. After 
the final treatment, we asked the intervention group if, 
in general, they had experienced a beneficial effect from 
the acupuncture treatment.
sample size
The necessary sample size for the RCT was determined 
from reports on the primary outcome HF and the two 
secondary outcome DNS and MSSP in the MSQ valida-
tion study.29 We considered a reduction in a scale score as 
clinically relevant if it corresponded to a reduction from 
‘a lot’ to ‘quite a bit’ on a global item regarding whether 
the respondent was bothered by menopausal symptoms. 
In the MSQ validation study, women who were bothered 
‘a lot’ had a mean score of 4.98 on the HF scale, and 
women who were bothered ‘quite a bit’ had a mean score 
of 3.48 on the HF scale. Both groups have an SD around 
1.4. To detect such a reduction on the HF scale with 
90% power, 5% level of significance and accounting for 
20% dropouts, we needed to include 48 participants (24 
Table 1 Acupuncture points and location
CV-3 Anterior midline, 1 cun* proximal to the symphysis. 
Insertion depth; perpendicularly 0.5–1 cm.
CV-4 Anterior midline, 1 cun proximal to CV-3 and 3 
cun inferior to the umbilicus. Insertion depth; 
perpendicularly 0.5–1 cm.
LR-8 Medial side of the knee, in the depression anterior/
medial to the tendons of semimembranosus and the 
semitendinosus muscles, at the medial end of the 
popliteal crease. Insertion depth; perpendicularly 
1.5–2 cm.
SP-9 Under the medial condyle of tibia in a depression 
between the posterior tibia and m. gastrocnemius. 
Insertion depth; perpendicularly 2–3 cm.
SP-6 Three cun proximal to the prominent part of the 
medial malleoli, on the medial and posterior border 
of the tibia. Insertion depth; perpendicularly 1–3 cm.
*A cun is an acupuncture measurement unit. One cun corresponds 
to the width of the study subject’s thumb.
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participants in each group). To achieve a similar power 
on the DNS and MSSP scales, we needed 56 and 68 partic-
ipants, respectively.
randomisation
The allocation sequence was computer generated using 
SAS software (V.9.4) and kept by a person independent 
of the project organisation (affiliated to the Centre for 
Health Economic Research, University of Southern 
Denmark). After enrolment, the independent person 
allocated the participants to one of the two randomisa-
tion groups. The participants were subsequently referred 
to the acupuncturist. This process ensured that allocation 
could not be guessed or later changed, thereby securing 
allocation concealment. Randomisation was done in 
blocks, with random block sizes, and stratified by age 
(aged 40–55 years or 56–65 years) and level of symptoms 
(experiencing hot flushes ‘quite a bit’ or ‘a lot’).
statistical methods
For each of the primary and secondary outcomes, the 
up to three assessments for each woman were modelled 
with a linear mixed model with a level for each time point 
for each randomisation group; the inherent correlation 
between observations on the same woman was accounted 
for by the inclusion of a subject-random effect. The effect 
of the intervention was estimated at week 3 and week 
6 by the mean difference of the outcome beyond the 
difference already present at baseline and assessed by the 
appropriate Wald test in the model. The model addition-
ally included as covariates the dichotomisations used in 
the stratification of the randomisation: age and level of 
symptoms. The analysis was done intention to treat. Four 
or more treatments were considered adequate adherence.
All outcomes were Rasch validated, which implies suffi-
ciency; that is, the sum-score carries all information of the 
measurement. Therefore, a score on one of scales of 4 is 
more than a score of 3 and so on. This justifies the use of 
the scores of the scales as continuously valued outcome 
variables in our analyses. A check of the assumptions of 
the linear regression analyses, aided by the Central Limit 
Theorem, justifies the comparison of the untransformed 
mean difference in scores and the use of the asymptotic 
Wald t-tests. Finally, the mixed model approach consti-
tutes a first line defence against differential dropout.
Table 2 Baseline characteristics for each group of women
Control 
(n=34)
Intervention 
(n=36)
Age (years), mean (SD) 54.1 (5) 55.3 (4)
Age (years), n (%)
  40–55 13 (38) 17 (47)
  56–65 21 (62) 19 (53)
Employment, n (%)
  Employed 31 (91) 32 (89)
  Unemployed 3 (9) 4 (11)
Education, n (%)
  Vocational 8 (24) 8 (22)
  Short (<3 years) 4 (12) 3 (8)
  Long (≥3 years) 16 (47) 22 (61)
  Other 6 (18) 3 (8)
Household, n (%)
  Living alone 1 (3) 5 (14)
  Living with others 33 (97) 31 (86)
Physical activity, n (%)
  No physical activity 7 (21) 3 (8)
  1–3 times per week 20 (59) 23 (64)
  ≥4 times per week 7 (21) 10 (28)
Smoking, n (%)
  Yes 1 (3) 2 (6)
  No 33 (97) 34 (94)
Alcohol, n (%)
  No alcohol 1 (3) 8 (22)
  ≤14 units per week 29 (85) 19 (53)
  >14 units per week 4 (12) 9 (25)
  Body mass index (kg/m2), 
mean (SD)
25.5 (5) 24.9 (3)
Menstruation in the last year, n (%)
  Yes 7 (21) 11 (31)
  No 27 (79) 25 (69)
Number of births, n (%)
  None 3 (9) 2 (6)
  One 5 (15) 8 (22)
  Two 20 (59) 18 (50)
  More than two 6 (18) 8 (22)
Incontinentia, n (%)
  No 13 (38) 10 (28)
  Yes 21 (62) 26 (72)
Chronic disease, n (%)
  Yes 5 (15) 8 (22)
  No 29 (85) 28 (78)
Previous experience with alternative 
treatment, n (%)
  No 8 (24) 10 (28)
Continued
Control 
(n=34)
Intervention 
(n=36)
  Yes 26 (77) 26 (72)
Duration of hot flushes (years), 
mean (SD)
3.41 (3) 4.59 (4)
Hot flushes (HF), n (%)
  HF=4 20 (59) 15 (42)
  HF>4 14 (41) 21 (58)
Table 2 Continued 
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The statistical significance was assessed controlling for 
the false discovery rate at 5% with the method of Benja-
mini and Hochberg.35 SAS V.9.4 was used for the analyses.
blinding
Statistician and outcome assessors were blinded until all 
analyses were completed. Participants and acupuncturist 
were not blinded.
Patient involvement
In the development of the research question, and in the 
design of the study, the development and content validity 
of the outcome measure (MSQ) was ensured by qualita-
tive interviews with women who experienced bothersome 
menopausal symptoms.29 During this process, the rele-
vance of this present study was also confirmed. Patients 
were not involved in the recruitment or conduction of 
the study. The burden of intervention was not assessed 
by the participants. When results are published, they 
will be disseminated to the Danish College of General 
Practitioners, the DSEA, the DMAS, the project research 
homepage,30 local newspaper and Danish women’s life-
style magazines.
results
We interviewed 207 women for eligibility, of which 70 met 
the inclusion criteria and were enrolled over a 3-month 
period: we allocated 36 participants to the intervention 
group and 34 participants to the control group. The 
number of participants treated by a single acupuncturist 
ranged from minimum 1 to maximum 16 (including the 
delayed treatment of the control group). No markedly 
differences in baseline characteristics between the rando-
misation groups were identified (table 2). Inspection of 
the residuals of the models did not reveal serious vari-
ance heterogeneity. Inspection of Cook’s D did not reveal 
subjects that were particularly influential to the results. 
Four participants dropped out: one in the intervention 
Figure 1 Trial flow. HF, hot flushes; HT, hormone therapy.
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group and three in the control group (figure 1). The 
MSQ response rate was 100% for all remaining partici-
pants at all assessments points. The adherence to treat-
ment was very high: 34 out of 36 received all five planned 
acupuncture treatments, and one received four out of five 
treatments. We collected primary data between October 
2016 and February 2017.
The analyses of the observed raw scores demon-
strated generally lower means in the intervention group 
compared with the control group when followed up 
(online supplementary appendix 4).
The developments in the MSQ scales across the two 
randomisation groups over the study period are presented 
in figures 2 and 3.
Primary outcome
The intervention group was significantly less bothered by 
HFs at 6 weeks: Δ −1.6 (95% CI [−2.3 to −0.8]; p<0.0001). 
This difference was also statistically significant at 3 weeks: 
Δ −1.5 (95% CI [−2.2 to −0.7]; p=0.0002). (table 3).
secondary outcomes
Statistically significant differences were identified at 
6 weeks in the following secondary outcomes: DNS: Δ 
−1.2 (95% CI [−2.0 to −0.4]; p=0.0056); GS: Δ −0.9 (95% 
CI [−1.6 to −0.2] p=0.0086); MSSP: Δ −1.8 (95% CI [−2.7 
to −1.0]; p<0.0001); EM: Δ −3.4 (95% CI [−5.3 to −1.4]; 
p=0.0008); PHY: Δ −1.7 (95% CI [−3 to −0.4]; p=0.010) 
and SH Δ −1.5 (95% CI [−2.5 to −0.6]; p=0.0021) (table 3). 
This difference was also statistically significant at 3 weeks 
in EM: Δ −3.2 (95% CI [−5.1 to −1.2]; p=0.0015) and SH: 
Δ −1.4 (95% CI [−2.4 to −0.5]; p=0.0036) (table 3).
In the intervention group, 80% of participants reported 
a general beneficial treatment effect after 6 weeks.
harms and adverse events
No serious harms or adverse events were reported in 
the intervention group. Four participants reported mild 
potential adverse effects: one experienced tiredness and 
headache after treatment; another experienced more hot 
flushes in some of the weeks but reported this to be asso-
ciated with increased stress in her personal and profes-
sional life; one had to urinate more frequently; and one 
experienced tingling in the leg where the needle had 
been placed.
Besides the four participants who reported mild poten-
tial adverse effects, one participant dropped out because 
she found the needling unpleasant (figure 1). However, 
this was not unexpected as acupuncture needling in some 
Figure 2 Development of the HF, DNS, GS and MSSP scales over the study period. DNS, day-and-night sweats; GS, general 
sweating; HF, hot flushes; MSSP, menopausal-specific sleeping problems. The error bars denote the 95% CI of the estimate of 
the outcome means for each randomisation group for each time point.
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cases is experienced as a bit unpleasant (needles are 
inserted into the body which might be a bit unpleasant).
DIsCussIOn
Principal findings
The standardised acupuncture treatment used in the 
present study reduced the HF, DNS, GS, MSSP, EM, PHY 
and SH scales after 5 weekly treatments, and the HF, EM 
and SH scales were reduced after two acupuncture treat-
ments. The intervention did not significantly reduce the 
remaining MSQ scales, but we did also not expect to see 
this because this study was underpowered regarding these 
scales. Additionally, since significant reductions were only 
found in some of the scales, our findings emphasise that 
the intervention was targeted to menopausal symptoms 
and are not an artefact of general care. The acupuncture 
treatment was well tolerated: one participant dropped 
out, and only four participants reported mild potential 
adverse effects. No serious harms were reported.
strengths and weaknesses of the study
The intervention period was relatively brief. However, 
it served to test a pragmatic, standardised and brief 
acupuncture approach manageable by both GPs and 
participants. Therefore, the suitability of the treatment 
outlined in this study in day-to-day primary care is high. 
The study had very high participant adherence: only 
4 out of 70 participants dropped out. The remaining 
participants fulfilled the criteria for adequate treatment 
adherence and had a 100% MSQ response rate, demon-
strating that the intervention was well tolerated. The fact 
that the control group was also offered treatment after 
6 weeks probably contributed to the high adherence rate. 
Finally, all participants were offered the same interven-
tion, and cointerventions for menopausal symptoms were 
not allowed in the study period, thereby reducing the risk 
of performance bias. Not all menopausal women need or 
request treatment, and we believe this acupuncture inter-
vention is most relevant to women who experience moder-
ate-to-severe menopausal symptoms. We wanted to avoid 
outcomes confounded by cofactors such as severe illness, 
other medications or cointerventions, and since the study 
took place in primary care, the participants should reflect 
healthy women attending their GP requesting treatment 
for menopausal symptoms. We believe the participants are 
representative of such women and that our standardised 
and pragmatic intervention could easily be transferred to 
most clinical settings.
Another strength in this study was the use of a condi-
tion-specific PROM (MSQ) with high-content validity 
and adequate psychometric properties ensuring high 
construct validity of the study measurements. More-
over, data from the MSQ validation study29 was used to 
generate the power calculation based on relevant clin-
ical effects that ensured adequate sample size. We did 
not use a physiological measurement, for example, skin 
conductance or temperature (which would probably have 
been technically difficult) because we believe PROMs are 
the most appropriate method to obtain information on 
participants’ own perception of their symptoms.36 The 
recall time frame in this study was 1 week, which reduced 
the risk of recall bias.
The placebo effect plays an important role in all 
interventional studies and is influenced by expectations 
and beliefs. All GPs were certified acupuncturists and 
although they were instructed to behave neutrally, their 
beliefs in acupuncture could have affected their interac-
tion with the participants and possibly have intensified a 
placebo effect. However, correct acupuncture techniques 
requires extensive training, and using GPs without such 
training would have been wrong and misleading. In 
addition, all participants were volunteers with presum-
ably expectations of a beneficial effect. This might have 
enhanced the placebo effect in the intervention group 
and could have caused a nocebo effect in the control 
group. However, we did not see such deterioration in the 
control group. In fact, the control group showed a trend 
of improvement, in particular in the HF scale, which may 
Figure 3 Development of the remaining (EM, MEM, SH, 
PHY, ABD, URIN and SEX) MSQ scales and the single 
item over the study period. ABD, abdominal symptoms; 
EM, emotional symptoms; MEM, memory changes; MSQ, 
MenoScores Questionnaire; PHY, physical symptoms; SEX, 
sexual symptoms; SH, skin and hair symptoms; URIN, urinary 
and vaginal symptoms.
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be explained by a regression to the mean. The lack of 
a sufficient acupuncture placebo comparator is a major 
limitation in acupuncture studies, including this study. 
In WMA theories, sham (placebo) acupuncture is not 
perceived as inactive but rather another, although less 
effective, form of needling.31 32 Furthermore, a meta-anal-
ysis concluded that non-specific effects associated with 
sham acupuncture are often moderately large and might 
be larger than other placebo interventions.37 If sham is 
not inactive, a study testing sham versus real acupunc-
ture is not a placebo-controlled study but rather a study 
testing two different types of acupuncture. Therefore, we 
decided to investigate the impact of acupuncture versus 
no treatment. An important weakness of the present 
study is that the identified positive effects from acupunc-
ture treatment could be caused by a placebo effect and 
not a specific physiological effect of needling. However, 
our aim was not to distinguish between specific and 
non-specific effects of needling but to investigate the 
impact of acupuncture versus no treatment. We found 
that the acupuncture treatment used in this study had 
an important clinical effect. If we ignore these findings, 
due to a lack of knowledge about possible specific effects 
of acupuncture, women with moderate-to-severe meno-
pausal symptoms could miss out on a low cost and effec-
tive treatment with only minor potential adverse effects.
One final limitation was that blinding of acupunctur-
ists and participants in this study design was not possible. 
However, we secured blinding of the statistician and 
outcome assessors until all analyses were completed.
Comparison with other studies
Some previous studies have demonstrated real acupunc-
ture to be significantly superior to sham acupuncture.38–40 
However, a Cochrane review from 2013 regarding 
acupuncture for menopausal HFs found no significant 
differences between real acupuncture compared with 
sham but a beneficial effect of acupuncture compared 
with no treatment and that acupuncture was inferior to 
HT. The evidence was in general of poor quality, and 
further high quality studies were recommended.18 Results 
from two recent studies, one comparing real acupunc-
ture with sham41 and one comparing acupuncture with 
no treatment,42 confirm the findings reported in the 
Cochrane review.
The present study demonstrates that acupuncture 
is significantly superior to no treatment. Our study was 
based on WMA theories, while most previous studies 
were based on traditional Chinese medicine theories 
and diagnoses18 21 38–46 involving the concepts of yin/
yang and circulation of qi.32 33 Most previous studies had 
longer intervention periods and/or more treatment 
sessions21 39–50 and several studies used individualised 
treatment with variation in the selection of acupuncture 
points.21 40 42 43 46 Tailored treatments might be a truer 
reflection of the actual clinical context. However, in an 
RCT, we believe that treatment should be standardised 
so that the intervention can be replicated. Some studies 
differ from this study by including patients treated 
for breast cancer,38 39 44 45 which makes it difficult to 
compare results. In contrary to our study, some studies 
Table 3 Differences in means, primary and secondary outcomes
Week 0 (baseline)* Week 3† Week 6†
Δ (95% CI) Δ (95% CI) P value Δ (95% CI) P value
Hot flushes 0.1 (−0.6 to 0.7) −1.5 (−2.2 to −0.7) 0.0002‡ −1.6 (−2.3 to −0.8) <0.0001‡
Day-and-night sweats 0.0 (− 0.9 to 0.8) −1 (−1.8 to −0.1) 0.024 −1.2 (−2.0 to −0.4) 0.0056‡
General sweating 0.0 (−0.6 to 0.6) −0.6 (−1.3 to 0.1) 0.091 −0.9 (−1.6 to −0.2) 0.0086‡
Menopausal-specific sleeping 
problems 0.2 (−0.5 to 1) −0.9 (−1.7;- 0.1) 0.033 −1.8 (−2.7 to −1.0) <0.0001‡
Emotional symptoms 1.0 (−1.5 to 3.5) −3.2 (−5.1 to −1.2) 0.0015‡ −3.4 (−5.3 to −1.4) 0.0008‡
Memory changes −0.2 (−0.8 to 0.4) −0.5 (−1.0 to 0.1) 0.11 −0.2 (−0.8 to 0.1) 0.49
Physical symptoms 0.1 (−1.5 to 1.6) −1.3 (−2.6;- 0.0) 0.049 −1.7 (−3 to −0.4) 0.010‡
Urinary and vaginal symptoms 0.8 (0.1 to 1.5) −0.4 (−1.1 to 0.3) 0.21 −0.8 (−1.5 to −0.1) 0.025
Abdominal symptoms 0.1 (−0.6 to 0.8) −0.3 (−1 to 0.4) 0.38 −0.7 (−1.4 to 0.0) 0.042
Skin and hair symptoms 0.3 (−0.7 to 1.4) −1.4 (−2.4 to −0.5) 0.0036‡ −1.5 (−2.5 to −0.6) 0.0021‡
Sexual symptoms −0.2 (−1 to 0.7) −0.7 (−1.4 to −0.1) 0.032 −0.3 (−0.8 to 0.5) 0.69
Tiredness 0.1 (−0.3 to 0.5) −0.3 (−0.8 to 0.1) 0.15 −0.5 (−0.9 to 0.0) 0.049
Differences in mean scores between the randomization groups at each of the follow-up time points.
Negative values Δ=less symptoms in the intervention group.
*Difference in mean score of intervention relative to control, adjusted for stratification factors (age and level of symptoms [‘quite a bit’ or ‘a lot’ 
HF]).
†Difference in mean score of intervention relative to control beyond the difference already present at week 0 (baseline), adjusted for 
stratification factors (age and level of symptoms [‘quite a bit’ or ‘a lot’ HF]).
‡Significant at a 0.01 level to control for the false discovery rate at 0.05.
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allowed other cointerventions (eg, adjuvant antihormone 
therapy, cystostaticum, clonidine, antidepressants, HT or 
other alternative remedies),21 38 39 41 42 44 which might have 
affected their outcomes. Finally, some studies assessed 
other relevant secondary outcomes such as quality of life, 
hot flush interference and sleep quality, and one study 
also assessed plasma oestradiol. Most studies used self-re-
ported outcomes, but in several of them, the validation 
of the outcome measures was lacking, unclear or not 
reported.38 39 44 45 We did not use a quality of life measure, 
because we did not find a Rasch validated quality of life 
instrument for our target group. The MSQ validation 
ensured that all aspects considered important by meno-
pausal women themselves were covered by the MSQ 
scales. We would expect that a reduction in the HF, DNS, 
GS, MSSP, EM, PHY and SH scales may ultimately have a 
positive indirect impact on a menopausal woman’s overall 
sense of well-being and quality of life. To our knowledge, 
this study is the only one to use a PROM that is condi-
tion specific with high-content validity and psychometri-
cally Rasch validated.
Meaning of the study: possible explanations and implications 
for clinicians and policymakers
The lack of a proper acupuncture placebo comparator 
has major implications for conducting and interpreting 
acupuncture studies. Therefore, we need to continue 
the discussion about what level of evidence should be 
accepted as sufficient for a treatment to be considered 
effective. This is particularly the case when we cannot 
accurately explain the underlying mechanism behind 
the treatment, nor determine how much of the effect is 
caused by placebo. In addition, it is important to note 
that in the present study, the intervention was targeted at 
menopausal symptoms and subsequently demonstrated a 
targeted effect, not an improvement across all symptoms. 
We also need to take the balance between benefits and 
harms into consideration. There is strong evidence that 
acupuncture for menopausal symptoms is without serious 
harms. Thus, requirements for evidence of the efficacy 
of acupuncture treatment might be less rigorous. On 
the contrary, acupuncture treatment in a private setting 
(ie, outside a publicly funded healthcare system) might 
involve considerable personal expense and opportunity 
costs.
We consider the intervention in this study to be low 
cost, both to the individual and to the health system, but 
this needs to be further investigated and included in a 
discussion of value-based healthcare.51
Future research
The long-term effect, the characteristics of women who 
benefit from acupuncture treatment, cost-effectiveness, 
the underlying mechanism of needling and the impact of 
placebo need further investigation.
COnClusIOn
A standardised acupuncture treatment gives women 
suffering from moderate-to-severe menopausal symptoms 
a clinically relevant reduction in HFs, DNS, GS, MSSP, 
EM, PHY and SH. Acupuncture for menopausal symp-
toms is a realistic option for women who cannot or do not 
wish to use HT. Women seeking acupuncture treatment 
for menopausal symptoms should be informed of the 
current evidence, and its limitations, so they can integrate 
this with personal preferences and values in their deci-
sion making. This study has high methodological quality, 
adequate power, a validated outcome measure and suffi-
cient reporting leading to high validity of the study and 
findings. Furthermore, this study use a pragmatic, stan-
dardised and brief intervention that leads to findings that 
may have a higher chance of being implemented and 
thereby are more likely to lead to new treatment options 
for menopausal women.
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